11 results about "Gestational age" patented technology

This invention discloses a method, apparatus, device, and storage medium for medication risk assessment during pregnancy, relating to the interdisciplinary fields of medical information technology and clinical pharmacy. The method includes: receiving patient information and proposed medication regimen information, whereby the patient information includes gestational age and information on multiple comorbidities; calling the corresponding gestational age adaptive risk weight matrix based on gestational age, weighting the patient features to generate a weighted feature vector, and inputting this vector into a machine learning model to obtain an initial medication risk score; based on a constructed heterogeneous knowledge graph, using entities corresponding to multiple comorbidities and medication regimen information as query starting points, performing multi-hop reasoning to determine the existence and severity of conflicting paths; if a conflicting path is detected, revising the initial medication risk score according to the severity of the conflict to generate a final risk score. This application enables individualized, interpretable, and evidence-based intelligent risk assessment of proposed medication regimens for pregnant women with multiple comorbidities.

A method for fetal risk monitoring based on gestational physiological characteristics includes the following steps: collecting physiological indicator data of pregnant women during pregnancy; preprocessing the physiological indicator data; establishing a multimodal model, inputting the preprocessed physiological indicator data into the multimodal model, which outputs the types of abnormal physiological indicators, as well as the fetal risk score and risk level; implementing targeted non-invasive intervention measures based on the risk level and the types of abnormal physiological indicators; continuously monitoring the physiological indicator data after intervention and dynamically updating the risk assessment results. The fetal risk monitoring method and system based on gestational physiological characteristics provided by this invention can monitor the health risks of the fetus based on the physiological characteristics of pregnant women during pregnancy, thereby facilitating prediction before health risks to the fetus occur and helping medical staff gain sufficient intervention time.

This application provides a method, device, and electronic device for assessing medication risks during pregnancy. Through automated knowledge graph querying and risk calculation, a risk assessment report can be quickly generated, reducing the time and cognitive load required for doctors to manually review literature and memorize complex rules. Simultaneously, it can match the current stage of medication risk to the patient's specific gestational age and perform comprehensive, real-time risk assessment based on the pregnant patient's real-time physiological indicators. This avoids the shortcomings of risk assessments that fail to consider gestational changes and individual patient differences, improving the accuracy of risk assessment. Furthermore, by acquiring medication information and physiological indicators, it can continuously and in real-time calculate the risk of medication use based on the patient's actual medication behavior and changes in physiological state during medication. Based on the real-time risk assessment results, medication guidance can be provided to patients, enhancing their understanding of the medication regimen and reducing the risks of medication use during pregnancy.

This invention provides a perinatal full-cycle intelligent intervention method based on multi-source heterogeneous data fusion, comprising: step S100, simultaneously collecting subjective self-reported data from pregnant women, real-time physiological data from wearable devices, and heterogeneous clinical examination data to construct a multi-dimensional spatiotemporal data pool; step S200, establishing a unified time base axis with gestational age and absolute time as dual coordinate axes, and extracting feature vectors from the data in the multi-dimensional spatiotemporal data pool at fixed time steps; step S300, calculating the real-time global comprehensive risk index RI based on the feature vectors; step S400, when RI exceeds the first dynamic threshold T1, the system triggers a level-one warning; when RI exceeds the second dynamic threshold T2 and a preset acute-critical feature operator is identified, the system triggers a level-two warning, and simultaneously generates an admission preparation list and sends a rescue instruction to the hospital's emergency dispatch system.

The application discloses a kind of based on diet inflammation index gestational diabetes mellitus blood sugar management method, comprising the following steps: S1: input pregnant woman information;Obtain the personalized information of pregnant woman, including: gestational age, pre-pregnancy / current weight, blood sugar risk level, dietary intake frequency, food intake, diet inflammation index initial score;S2: calculate diet inflammation index;Calculate nutrient intake, standardization processing, inflammation weight calculation, calculation;S3: predict blood sugar risk through blood sugar risk prediction module, output risk level;S4: generate diet program, three meals structure, food combination and heat distribution through individualized diet intervention module;S5: monitor blood sugar, adjust menu according to blood sugar change.Can combine carbohydrate and inflammation, establish diet inflammation blood sugar management new mode, realize accurate management.

This invention relates to the field of medical data analysis, and more particularly to a method for assessing the risk of pregnancy outcomes in pregnant women based on multifactor feature analysis. The method includes: acquiring individual measured time-series datasets and baseline reference data for physiological expectations; obtaining a gestational age-specific pathological surge penalty factor by weighting the ratio of angiogenic factors to anti-angiogenic factors; obtaining a cross-system pathological cascade time coupling factor by temporally tracing and coupling abnormal deviations in vascular system indicators and blood system indicators; obtaining a fused feature vector by correcting and fusing the initial linear regression slope features; and obtaining the pregnancy outcome risk assessment result by performing machine learning prediction on the fused feature vector. This method solves the problem that existing prediction methods based on linear regression slope extraction and feature splicing cannot effectively identify gestational age-specific early high-risk signals and cross-system short-term pathological cascade signals.

A method for diagnosing or predicting preeclampsia in a pregnant woman or determining whether a pregnant woman is at risk of developing preeclampsia is provided, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman selected from the group comprising: (i) one or more of mean arterial pressure, BMI at sampling, ΔBMI, gestational age, and ΔBMI / GA; (ii) maternal age; (iii) one or more of urinary protein level and ratio of urinary protein level (such as total urinary protein) to urinary creatinine level; (iv) one or more of history of preeclampsia in previous pregnancies and having received antihypertensive medication; and (v) any combination of (i)-(iv), b) determining whether the pregnant woman has misfolded proteins or misfolded protein aggregates in her urine, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) with the level of misfolded proteins or misfolded protein aggregates in the pregnant woman's urine to diagnose or predict preeclampsia or determine the risk of preeclampsia.

Embodiments of this disclosure relate to methods and compositions relating to the optimization and selection of umbilical cord blood units for the production of immune cells, such as natural killer (NK) cells, for use in adoptive cell therapy. In certain embodiments, specific properties of an umbilical cord blood unit and / or the properties of cells obtained therefrom are analyzed. If a threshold measurement is met for one or more properties of the umbilical cord blood unit and / or the properties of cells obtained therefrom, the umbilical cord blood unit is used as a source for the production of immune cells. Specific properties to be measured include, for example, the viability of umbilical cord blood cells, the time from birth to cryopreservation of the umbilical cord blood unit, the total nucleated cell recovery rate, infant weight, infant sex, maternal age, gestational age, CD34-positive cell percentage, and / or nucleated red blood cell content. These properties may be determined before and / or after cryopreservation.

The present disclosure provides a non-invasive method for early diagnosis of a placental pathology comprising an abnormal formation or arrangement of a placenta in a uterus of a mammalian female subject during pregnancy. Early diagnosis can lead to an improved maternal outcome. The method comprises selectively purifying from plasma of maternal blood a population of small extracellular vesicles (small-EVs) expressing a placenta-specific surface biomarker. The extracellular vesicles comprise micro-RNA cargo. A cargo profile for the small EVs is determined by extracting RNA from the purified population of small EVs. Expression of small non-coding RNAs comprising one or more micro RNAs (miRNAs) encapsulated by the purified population of exosomes is then identified and quantified. The miRNA profile of the placenta specific EVs is then compared to the miRNA profile of a healthy control of the same approximate gestational age.

The present application relates to the field of intelligent medical technology, in particular to a pregnant period weight evaluation and intervention tracking intelligent management system, comprising: a whole pregnancy cycle data acquisition module for acquiring pregnant women's whole pregnancy cycle body weight composition, diet and exercise behavior, and maternal and infant health index data; a filing module for constructing a structured individual health record and generating a standardized weight management monitoring data set; an intelligent weight evaluation and intervention scheme generation module for performing pregnant women's gestational age adaptation correlation influence evaluation and generating gestational age stage and daily personalized weight intervention schemes; a real-time intervention tracking and risk early warning module for performing real-time evaluation, generating visual tracking correction prompts, and adjusting intervention intensity by grade through a contrast learning algorithm; and a compliance management and scheme iteration optimization module for generating multi-scene reminders and iteratively updating a basic framework of the next day's generated scheme. Thus, the problems of difficulty in adapting to the differentiated needs of different pregnant women and difficulty in timely responding to unexpected situations during pregnancy in the prior art are solved.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.